David D. Kim

Perspective and Costing in Cost-Effectiveness Analysis, 1974–2018

David D. Kim, Madison C. Silver, Natalia Kunst et al. · PharmacoEconomics · 2020 · 272 citations · Full text

Pharmacy, Pharmacoeconomics, Comparative Effectiveness Research +16

Species-specific disruption of STING-dependent antiviral cellular defenses by the Zika virus NS2B3 protease

Qiang Ding, Jenna M. Gaska, Florian Douam et al. · Proceedings of the National Academy of Sciences · 2018 · 186 citations · Full text

Life Sciences, Infectious Diseases, Molecular Biology +14

Use and Misuse of Cost-Effectiveness Analysis Thresholds in Low- and Middle-Income Countries: Trends in Cost-per-DALY Studies

Ashley A. Leech, David D. Kim, Joshua T. Cohen et al. · Value in Health · 2018 · 179 citations · Full text

Pharmacy, Health Sciences, Pharmacoeconomics +17

Use of magnetic resonance imaging in rectal cancer patients: Society of Abdominal Radiology (SAR) rectal cancer disease-focused panel (DFP) recommendations 2017

Marc J. Gollub, Supreeta Arya, Regina G. H. Beets‐Tan et al. · Abdominal Radiology · 2018 · 171 citations

Medicine, Oncology, Radiology +17

Assessment of Racial/Ethnic and Income Disparities in the Prescription of Opioids and Other Controlled Medications in California

Joseph Friedman, David D. Kim, Todd Schneberk et al. · JAMA Internal Medicine · 2019 · 167 citations · Full text

Public Health, Community Health, Population Health Sciences +15